Hospital Acquired Pneumonia Clinical Trial
Official title:
Validity of Biological Material Sampling in Patients With Hospital-acquired Pneumonia
The main objective of project is to compare validity of sampling methods performed routinely (bronchial secretion, stomach content, oropharyngeal smear) for determination of etiological agent responsible for hospital-acquired pneumonia (HAP) in critically ill patients to bronchoscopy-assisted protected brush method. Evaluation of the present clinical praxis using bronchial secretion sampling in HAP diagnostics and detection of the most common etiological agents in patients with HAP are other priorities of the project. Aiming to confirm or exclude the diagnosis of HAP, determine the sources and possible routes of bacterial pathogens transmission molecular biology analysis of etiological agents is performed. Finally, percentage of HAP etiological agents resistant to initial empiric antibiotic therapy will be observed.
The main objective of project will be comparing validity of sampling methods performed
routinely (bronchial secretion, stomach content, oropharyngeal smear) for determination of
etiological agent responsible for hospital-acquired pneumonia (HAP) in critically ill
patients to bronchoscopy-assisted protected brush method. Obtained results of different
methods will enable to determine if the bronchial secretion sample, stomach content sample
or oropharyngeal smear are comparable to precise but technically difficult protected brush.
Evaluation of the present clinical praxis using bronchial secretion sampling in HAP
diagnostics and detection of the most common etiological agents in patients with HAP will be
other priorities of the project. The role of atypical and fungal pathogens in HAP initiation
will be discovered as well. Aiming to confirm or exclude the diagnosis of HAP, determine the
sources and possible routes of bacterial pathogens transmission molecular biology analysis
of etiological agents will be performed. Finally, percentage of HAP etiological agents
resistant to initial empiric antibiotic therapy will be observed.
Project fulfills program objectives of molecular-biologic approaches and research support in
infectious diseases domain. It will make contribution to faster and more precise HAP
diagnosis and adequate antibiotic therapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03348579 -
Hospital-acquired Pneumonia in Intensive Care Unit
|
||
| Completed |
NCT02454114 -
HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections
|
N/A | |
| Recruiting |
NCT05487586 -
Real-World Study of Ceftazidime Avibactam in China
|
||
| Completed |
NCT01577862 -
Colistin and Rifampicin for MDR-Acinetobacter
|
Phase 3 | |
| Completed |
NCT01883869 -
Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor
|
Phase 1 | |
| Recruiting |
NCT02203110 -
The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia
|
N/A | |
| Completed |
NCT01769742 -
Early Mobility Bundle to Prevent Hospital Acquired Pneumonia (HAP) in Medical Inpatients
|
N/A | |
| Not yet recruiting |
NCT06269900 -
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
|
Phase 3 | |
| Completed |
NCT04882085 -
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
|
Phase 4 | |
| Completed |
NCT02058004 -
Does Cricoid Pressure Reduce the Risk of Aspiration?
|
N/A |